Palmitoyl-Carnitine

Palmitoyl-Carnitine

SCHEMBL115183

CCCCCCCCCCCCCCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 1.00
MEN1 O00255 5/20 1.00
KMT2A Q03164 5/20 1.00
SLC25A20 O43772 3/20 1.00
TP53 P04637 3/20 1.00
TSHR P16473 3/20 1.00
CYP2D6 P10635 2/20 1.00
SLC6A5 Q9Y345 2/20 1.00
CYP2C9 P11712 2/20 1.00
HIF1A Q16665 2/20 1.00
CYP2C19 P33261 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
HSD17B10 Q99714 1/20 1.00
MAPK1 P28482 5/20 0.76
CYP1A2 P05177 4/20 0.76
GMNN O75496 3/20 0.76
LMNA P02545 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288673 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL19182624 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL8050598 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL288242 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL17164609 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL25373354 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
Palmitoyl-Carnitine SCHEMBL187668 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
Octanoylcarnitine SCHEMBL2915508 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL188470 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53
SCHEMBL198686 1.00 MAPT (1.00) MAPTMEN1KMT2ASLC25A20TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5110 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747627-A1 METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS Matterworks Inc (US) 2026-05-27 EP claimed
CN-119791058-B Pain rheumatism heat syndrome subtype modeling method, biomarker group application and detection method 广东省中医院(广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院) 2026-05-19 CN claimed
US-20260131089-A1 DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY APTARGROUP, INC. (US) 2026-05-14 US claimed
CN-122017090-A Biomarker combination for screening heart failure pleural effusion, application, system, equipment and medium 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 2026-05-12 CN claimed
US-20260125683-A1 TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-07 US claimed
US-20260120870-A1 ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT INNOBATION BIO CO LTD (KR) 2026-04-30 US claimed
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
US-12594388-B2 Device to deliver a predetermined amount of a substance to a natural orifice of the body APTARGROUP, INC. (US) 2026-04-07 US claimed
US-20260090984-A1 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS MEDIPRINT OPHTHALMICS INC. (US) 2026-04-02 US claimed
US-20260048146-A1 METHODS AND COMPOSITIONS FOR TREATING LEUKODYSTROPHIES BRIDGEBIO GENE THERAPY LLC (US) 2026-02-19 US claimed
WO-1995009651-A1 IMPROVEMENTS IN AND RELATING TO VACCINES PROTEUS MOLECULAR DESIGN LIMITED (GB) 1995-04-13 WO claimed
EP-0215697-B1 ACYLCARNITINES AS ABSORPTION-ENHANCING AGENTS FOR DRUG DELIVERY THROUGH MUCOUS MEMBRANES OF THE NASAL, BUCCAL, SUBLINGUAL AND VAGINAL COMPARTMENTS MERCK & CO. INC. (US) 1992-03-25 EP claimed
US-4963556-A ANTIVIRAL AGENTS MERCK & CO., INC. (US) 1990-10-16 US claimed
US-4963525-A POLYPEPTIDES MERCK & CO., INC. (US) 1990-10-16 US claimed
EP-0162764-B1 COMPOSITION AND METHOD FOR ENHANCING ABSORPTION OF DRUGS FROM GASTROINTESTINAL TRACT USING ACYLCARNITINES MERCK & CO. INC. (US) 1989-08-09 EP claimed
US-4847298-A DOPA COMPOUNDS OR ANTIBIOTICS MERCK & CO., INC. (US) 1989-07-11 US claimed
US-4731360-A Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments MERCK & CO., INC. (US) 1988-03-15 US claimed
EP-0215697-A2 Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments MERCK & CO. INC. (US) 1987-03-25 EP claimed
EP-0162764-A1 Composition and method for enhancing absorption of drugs from gastrointestinal tract using acylcarnitines MERCK & CO. INC. (US) 1985-11-27 EP claimed
US-4537772-A Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines MERCK & CO., INC. (US) 1985-08-27 US claimed